The ubiquitous interleukin-6: A time for reappraisal

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Fisman, Enrique Z ^a,b   Tenenbaum, Alexander ^a,b,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b Cardiovascular Diabetology Research Foundation   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; IL6 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; DRUG EFFECT; EDITORIAL; EXERCISE; HUMAN; INSULIN SENSITIVITY; LISTERIOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; STREPTOCOCCUS INFECTION; IMMUNOLOGY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INTERLEUKIN-6;

EID: 77957659561     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-62     Document Type: Editorial

References (74)

1. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature 2008, 51:949-952.
2. Steinbrich-Zöllner M, Grün JR, Kaiser T, Biesen R, Raba K, Wu P, Thiel A, Rudwaleit M, Sieper J, Burmester GR, Radbruch A, Grützkau A. From transcriptome to cytome: integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseases. Cytometry A 2008, 73:333-340.
3. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. 10.1067/mcp.2001.113989, 11240971, Biomarkers Definitions Working Group.
4. Azuaje F, Devaux Y, Wagner D. Computational biology for cardiovascular biomarker discovery. Brief Bioinform 2009, 10:367-377. 10.1093/bib/bbp008, 19276200.
5. Fisman EZ, Adler Y, Tenenbaum A. Biomarkers in cardiovascular diabetology: interleukins and matrixins. Adv Cardiol 2008, 45:44-64. full_text, 18230955.
6. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996, 127:263-271. 10.1016/S0021-9150(96)05968-0, 9125317.
7. Reuben DB, Ferrucci L, Wallace R, Tracy RP, Corti MC, Heimovitz H, Harris TB. The prognostic value of serum albumin in healthy older persons with low and high serum interleukin-6 (IL-6) levels. J Am Geriatr Soc 2000, 48:1404-1407.
8. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A. Elevated levels of IL-6 in unstable angina. Circulation 1996, 94:874-877.
9. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A. Elevated levels of C-reactive protein at discharge predicts recurrent instability in patients with unstable angina. Circulation 1999, 99:855-860.
10. Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, Dinarello CA, Maseri A. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999, 99:2079-2084.
11. Dinh W, Füth R, Nickl W, Krahn T, Ellinghaus P, Scheffold T, Bansemir L, Bufe A, Barroso MC, Lankisch M. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol 2009, 8:58. 10.1186/1475-2840-8-58, 2778641, 19909503.
12. Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010, 56:225-231. 10.1161/HYPERTENSIONAHA.109.148635, 20606113.
13. Fisman EZ, Benderly M, Esper RJ, Behar S, Boyko V, Adler Y, Tanne D, Matas Z, Tenenbaum A. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 2006, 98:14-18. 10.1016/j.amjcard.2006.01.045, 16784912.
14. Vahtola E, Louhelainen M, Forstén H, Merasto S, Raivio J, Kaheinen P, Kytö V, Tikkanen I, Levijoki J, Mervaala E. Sirtuin1-p53, forkhead box O3a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic Goto-Kakizaki rat. Cardiovasc Diabetol 2010, 9:5. 10.1186/1475-2840-9-5, 2835668, 20105289.
15. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817. 10.2337/diabetes.52.3.812, 12606524.
16. Snell-Bergeon JK, West NA, Mayer-Davis EJ, Liese AD, Marcovina SM, D'Agostino RB, Hamman RF, Dabelea D. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. J Clin Endocrinol Metab 2010, 95:2868-2876. 10.1210/jc.2009-1993, 20371668.
17. Rachon D, Mysliwska J, Suchecka-Rachon K, Semetkowska-Jurkiewicz B, Zorena K, Lysiak-Szydlowska W. Serum interleukin-6 levels and bone mineral density at the femoral neck in postmenopausal women with type 1 diabetes. Diabet Med 2003, 20:475-480. 10.1046/j.1464-5491.2003.00953.x, 12786682.
18. Tuttolomondo A, La Placa S, Di Raimondo D, Bellia C, Caruso A, Lo Sasso B, Guercio G, Diana G, Ciaccio M, Licata G, Pinto A. Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity. Cardiovasc Diabetol 2010, 9:50. 10.1186/1475-2840-9-50, 2946274, 20836881.
19. Kitamura A, Hasegawa G, Obayashi H, Kamiuchi K, Ishii M, Yano M, Tanaka T, Yamaguchi M, Shigeta H, Ogata M, Nakamura N, Yoshikawa T. Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med 2002, 19:1000-1005. 10.1046/j.1464-5491.2002.00844.x, 12647840.
20. Burkhardt K, Schwarz S, Pan C, Stelter F, Kotliar K, Von Eynatten M, Sollinger D, Lanzl I, Heemann U, Baumann M. Myeloid-related protein 8/14 complex describes microcirculatory alterations in patients with type 2 diabetes and nephropathy. Cardiovasc Diabetol 2009, 8:10. 10.1186/1475-2840-8-10, 2654885, 19232095.
21. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003, 149:1-38. full_text, 12687404.
22. Andrejko KM, Chen J, Deutschman CS. Intrahepatic STAT-3 activation and acute phase gene expression predict outcome after CLP sepsis in the rat. Am J Physiol 1998, 275:G1423-G1429.
23. Fernández-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001, 86:1154-1159. 10.1210/jc.86.3.1154, 11238501.
24. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, Wolf GT, Teknos TN. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008, 113:750-757. 10.1002/cncr.23615, 18536030.
25. Barut B, Chauhan D, Uchiyama H, Anderson KC. Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro. J Clin Invest 1993, 92:2346-2352. 10.1172/JCI116839, 288416, 8227350.
26. Alokail MS, Al-Daghri NM, Al-Attas OS, Hussain T. Combined effects of obesity and type 2 diabetes contribute to increased breast cancer risk in premenopausal women. Cardiovasc Diabetol 2009, 8:33. 10.1186/1475-2840-8-33, 2706231, 19545451.
27. Gauldie J, Northemann W, Fey GH. IL-6 functions as an exocrine hormone in inflammation. Hepatocytes undergoing acute phase responses require exogenous IL-6. J Immunol 1990, 15(144):3804-3808.
28. Peters M, Jacobs S, Ehlers M, Vollmer P, Müllberg J, Wolf E, Brem G, Meyer KH, Rose-John S. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996, 183:1399-1406. 10.1084/jem.183.4.1399, 2192475, 8666898.
29. Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, Moore EE, O'Keefe G, Sperry J, Remick D, Tompkins R, Maier RV, . Inflammation and the Host Response to Injury Collaborative Research Program Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure. Shock 2010, 34:346-351. 10.1097/SHK.0b013e3181d8e687, 20844410, Inflammation and the Host Response to Injury Collaborative Research Program.
30. Roytblat L, Rachinsky M, Fisher A, Greemberg L, Shapira Y, Douvdevani A, Gelman S. Raised interleukin-6 levels in obese patients. Obes Res 2000, 8:673-675. 10.1038/oby.2000.86, 11225716.
31. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, Keaney JF, Meigs JB, Lipinska I, Kathiresan S, Murabito JM, O'Donnell CJ, Benjamin EJ, Fox CS. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007, 116:1234-1241. 10.1161/CIRCULATIONAHA.107.710509, 17709633.
32. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51:3391-3399. 10.2337/diabetes.51.12.3391, 12453891.
33. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002, 87:2084-2089. 10.1210/jc.87.5.2084, 11994345.
34. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003, 278:45777-45784. 10.1074/jbc.M301977200, 12952969.
35. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 2005, 25:1268-73. 10.1161/01.ATV.0000163843.70369.12, 15790931.
36. Trøseid M, Seljeflot I, Arnesen H. The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol 2010, 9:11. 10.1186/1475-2840-9-11, 2858122, 20331890.
37. Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 2009, 8:61. 10.1186/1475-2840-8-61, 2789050, 19930630.
38. Heikkilä K, Ebrahim S, Rumley A, Lowe G, Lawlor DA. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women's Heart and Health Study. Cancer Epidemiol Biomarkers Prev 2007, 16:1155-1159. 10.1158/1055-9965.EPI-07-0093, 17548678.
39. Knudsen EC, Seljeflot I, Michael A, Eritsland J, Mangschau A, Müller C, Arnesen H, Andersen G. Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study. Cardiovasc Diabetol 2010, 9:47. 10.1186/1475-2840-9-47, 2940874, 20809989.
40. Ley SH, Hegele RA, Connelly PW, Harris SB, Mamakeesick M, Cao H, Gittelsohn J, Retnakaran R, Zinman B, Hanley AJ. Assessing the association of the HNF1A G319S variant with C-reactive protein in Aboriginal Canadians: a population-based epidemiological study. Cardiovasc Diabetol 2010, 9:39. 10.1186/1475-2840-9-39, 2929219, 20716378.
41. Osawa H, Doi Y, Makino H, Ninomiya T, Yonemoto K, Kawamura R, Hata J, Tanizaki Y, Iida M, Kiyohara Y. Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol 2009, 8:60. 10.1186/1475-2840-8-60, 2790441, 19922611.
42. Fisman EZ, Motro M, Tenenbaum A. Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof. Cardiovasc Diabetol 2003, 2:11. 10.1186/1475-2840-2-11, 212422, 14525620.
43. Pedersen BK, Febbraio MA. Point: Interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007, 102:814-816. 10.1152/japplphysiol.01208.2006, 17068210.
44. D'Auria L, Bonifati C, Mussi A, D'Agosto G, De Simone C, Giacalone B, Ferraro C, Ameglio F. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared with healthy subjects and correlate with disease activity. Eur Cytokine Netw 1997, 8:383-387.
45. Yamamura M, Yamada Y, Momita S, Kamihira S, Tomonaga M. Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival. Br J Haematol 1998, 100:129-134. 10.1046/j.1365-2141.1998.00538.x, 9450801.
46. Mathew M, Tay E, Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol 2010, 9:9. 10.1186/1475-2840-9-9, 2837624, 20158910.
47. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 2002, 16:1335-1347. 10.1096/fj.01-0876rev, 12205025.
48. Angstwurm MW, Gartner R, Ziegler-Heitbrock HW. Cyclic plasma IL-6 levels during normal menstrual cycle. Cytokine 1997, 9:370-374. 10.1006/cyto.1996.0178, 9195137.
49. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009, 8:23. 10.1186/1475-2840-8-23, 2688503, 19402896.
50. Sakamoto K, Arakawa H, Mita S, Ishiko T, Ikei S, Egami H, Hisano S, Ogawa M. Elevation of circulating interleukin 6 after surgery: factors influencing the serum level. Cytokine 1994, 6:181-186. 10.1016/1043-4666(94)90040-X, 8032001.
51. Keski-Nisula L, Hirvonen MR, Roponen M, Heinonen S, Pekkanen J. Spontaneous and stimulated interleukin-6 and tumor necrosis factor-alpha production at delivery and three months after birth. Eur Cytokine Netw 2004, 15:67-72.
52. Kitanovski L, Jazbec J, Hojker S, Gubina M, Derganc M. Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. Eur J Clin Microbiol Infect Dis 2006, 25:413-415. 10.1007/s10096-006-0143-x, 16767494.
53. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997, 18:428-432. 10.1016/S0167-5699(97)01103-1, 9293158.
54. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005, 98:1154-1162. 10.1152/japplphysiol.00164.2004, 15772055.
55. Bermudez LE, Wu M, Petrofsky M, Young LS. Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect Immun 1992, 60:4245-4252. 257459, 1328056.
56. Mancuso G, Tomasello F, Migliardo M, Delfino D, Cochran J, Cook JA, Teti G. Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infect Immun 1994, 62:4997-5002. 303218, 7927780.
57. van Vugt H, van Gool L, de Ridder L. Alpha 2 macroglobulin of the rat, and acute phase protein, mitigates the early course of endotoxin shock. Br J Exp Pathol 1986, 67:313-319.
58. Woloski BM, Smith EM, Meyer WJ, Fuller GM, Blalock JE. Corticotropin-releasing activity of monokines. Science 1985, 230:1035-1037. 10.1126/science.2997929, 2997929.
59. Liu Z, Simpson RJ, Cheers C. Recombinant interleukin-6 protects mice against experimental bacterial infection. Infect Immun 1992, 60:4402-4406. 257478, 1398949.
60. Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK. Acute interleukin-6 administration does not impair muscle glucose uptake or whole body glucose disposal in healthy humans. J Physiol 2003, 548:631-638. 10.1113/jphysiol.2002.032938, 2342867, 12640021.
61. Keller P, Keller C, Carey AL, Jauffred S, Fischer CP, Steensberg A, Pedersen BK. Interleukin-6 production by contracting human skeletal muscle: autocrine regulation by IL-6. Biochem Biophys Res Commun 2003, 310:550-554. 10.1016/j.bbrc.2003.09.048, 14521945.
62. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK. AMPK activity is diminished in tissues of the IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 2004, 320:449-454. 10.1016/j.bbrc.2004.05.188, 15219849.
63. Wojtaszewski JF, Jorgensen SB, Frosig C, Macdonald C, Birk JB, Richter EA. Insulin signalling: effects of prior exercise. Acta Physiol Scand 2003, 178:321-328. 10.1046/j.1365-201X.2003.01151.x, 12864736.
64. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. IL-6 increases insulin stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMPK. Diabetes 2006, 55:2688-2697. 10.2337/db05-1404, 17003332.
65. Richter EA, Mikines KJ, Galbo H, Kiens B. Effect of exercise on insulin action in human skeletal muscle. J Appl Physiol 1989, 66:876-885.
66. Mohr T, Andersen JL, Biering-Sørensen F, Galbo H, Bangsbo J, Wagner A, Kjaer M. Long-term adaptation to electrically induced cycle training in severe spinal cord injured individuals. Spinal Cord 1997, 35:1-16. 10.1038/sj.sc.3100343, 9025213.
67. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, Tanaka K, Wang W-Z, Mori C, Shiota K, Yoshida N, Kishimoto T. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci 1996, 93:407-411. 10.1073/pnas.93.1.407, 40247, 8552649.
68. Hennigan S, Kavanaugh A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2008, 4:767-775. 2621374, 19209259.
69. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006. 10.1016/S0140-6736(08)60454-7, 18358927.
70. Petersen AM, Pedersen BK. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 2006, 57(Suppl 10):43-51.
71. Pedersen BK, Fischer CP. Beneficial health effects of exercise--the role of IL-6 as a myokine. Trends Pharmacol Sci 2007, 28:152-156. 10.1016/j.tips.2007.02.002, 17331593.
72. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 2005, 54(Suppl 2):S114-124. 10.2337/diabetes.54.suppl_2.S114, 16306329.
73. Gadient RA, Otten UH. Interleukin-6 (IL-6) - a molecule with both beneficial and destructive potentials. Prog Neurobiol 1997, 52:379-90. 10.1016/S0301-0082(97)00021-X, 9304698.
74. Stevenson RL. Strange case of Dr Jekyll and Mr Hyde. 2008, Plattsburgh, NY: Tundra Books Inc.